Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels

Toxicology and Applied Pharmacology

Volumn 252, Issue 3, 2011, Pages 250-258

  Xia, Menghang ^a   Shahane, Sampada A ^a   Huang, Ruili ^a   Titus, Steven A ^a   Shum, Enoch ^b   Zhao, Yong ^b   Southall, Noel ^a   Zheng, Wei ^a   Witt, Kristine L ^c   Tice, Raymond R ^c   Austin, Christopher P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Cerep Inc   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cardiotoxicity; HERG; Long QT syndrome; NTP 1408 library; Patch clamp; QHTS; Tetra n octylammonium bromide; Thallium influx

Indexed keywords

ENVIRONMENTAL CHEMICAL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; QUATERNARY AMMONIUM DERIVATIVE; THALLIUM;

ARTICLE; CARDIOTOXICITY; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; GENE MUTATION; HEART MUSCLE POTENTIAL; HUMAN; HUMAN TISSUE; IC 50; IN VIVO STUDY; LONG QT SYNDROME; NUCLEOTIDE SEQUENCE; PATCH CLAMP; QT PROLONGATION; STRUCTURE ACTIVITY RELATION;

ARRHYTHMIAS, CARDIAC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; PATCH-CLAMP TECHNIQUES; QUATERNARY AMMONIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

TETRA;

EID: 79954631017     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.02.016     Document Type: Article

References (47)

1. Alvarez J., Montero M., Garcia-Sancho J. High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J. Biol. Chem. 1992, 267:11789-11793.
2. Belpomme D., Irigaray P., Hardell L., Clapp R., Montagnier L., Epstein S., Sasco A.J. The multitude and diversity of environmental carcinogens. Environ. Res. 2007, 105:414-429.
3. Bempong M.A., Hall E.V. Reproductive toxicology of 1,3-diphenylguanidine: analysis of induced sperm abnormalities in mice and hamsters and reproductive consequences in mice. J. Toxicol. Environ. Health 1983, 11:869-878.
4. Chouabe C., Drici M.D., Romey G., Barhanin J., Lazdunski M. HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol. Pharmacol. 1998, 54:695-703.
5. Cavalli A., Poluzzi E., De Ponti F., Recanatini M. Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers. J. Med. Chem. 2002, 45:3844-3853.
6. Collins F.S., Gray G.M., Bucher J.R. Toxicology. Transforming environmental health protection. Science 2008, 319:906-907.
7. Crinnion W.J. Chlorinated pesticides: threats to health and importance of detection. Altern. Med. Rev. 2009, 14:347-359.
8. Duan J.J., Ma J.H., Zhang P.H., Wang X.P., Zou A.R., Tu D.N. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol. Sin. 2007, 28:959-967.
9. Grace A.A., Camm A.J. Quinidine. N. Engl. J. Med. 1998, 338:35-45.
10. Gutman G.A., Chandy K.G., Grissmer S., Lazdunski M., McKinnon D., Pardo L.A., Robertson G.A., Rudy B., Sanguinetti M.C., Stuhmer W., Wang X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 2005, 57:473-508.
11. Heir E., Sundheim G., Holck A.L. Identification and characterization of quaternary ammonium compound resistant staphylococci from the food industry. Int. J. Food Microbiol. 1999, 48:211-219.
12. Inglese J., Auld D.S., Jadhav A., Johnson R.L., Simeonov A., Yasgar A., Zheng W., Austin C.P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA 2006, 103:11473-11478.
13. Kavlock R.J., Austin C.P., Tice R.R. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 2009, 29:485-487. discussion 492-487.
14. Kiss L., Bennett P.B., Uebele V.N., Koblan K.S., Kane S.A., Neagle B., Schroeder K. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev. Technol. 2003, 1:127-135.
15. Koeter H.B., Regnier J.F., van Marwijk M.W. Effect of oral administration of 1,3-diphenylguanidine on sperm morphology and male fertility in mice. Toxicology 1992, 71:173-179.
16. Ludomirsky A., Klein H.O., Sarelli P., Becker B., Hoffman S., Taitelman U., Barzilai J., Lang R., David D., DiSegni E., Kaplinsky E. Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am. J. Cardiol. 1982, 49:1654-1658.
17. McDonnell G., Russell A.D. Antiseptics and disinfectants: activity, action, and resistance. Clin. Microbiol. Rev. 1999, 12:147-179.
18. Montero M., Alvarez J., Garcia-Sancho J. Agonist-induced Ca2+ influx in human neutrophils is secondary to the emptying of intracellular calcium stores. Biochem. J. 1991, 277(Pt 1):73-79.
19. Toxicity Testing in the 21st Century: a Vision and A Strategy 2007, National Academy Press, Washington, DC. NRC (Ed.).
20. NTP Toxicity studies of 1,3-diphenylguanidine (CAS No. 102-06-7) administered in feed to F344/N rats and B6C3F1 mice. Toxic. Rep. Ser. 1995, 42:1-D6.
21. Perrin M.J., Kuchel P.W., Campbell T.J., Vandenberg J.I. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Mol. Pharmacol. 2008, 74:1443-1452.
22. Piskin G., Meijs M.M., van der Ham R., Bos J.D. Glove allergy due to 1,3-diphenylguanidine. Contact Dermat. 2006, 54:61-62.
23. Pongs O. Structural basis of voltage-gated K+ channel pharmacology. Trends Pharmacol. Sci. 1992, 13:359-365.
24. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
25. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 2005, 65(Suppl 2):1-10.
26. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 2006, 7:889-908.
27. Shamon S.D., Perez M.I. Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst. Rev. 2009, CD007655.
28. Song J.H., Nagata K., Tatebayashi H., Narahashi T. Interactions of tetramethrin, fenvalerate and DDT at the sodium channel in rat dorsal root ganglion neurons. Brain Res. 1996, 708:29-37.
29. Srivastava S., Sinha R., Roy D. Toxicological effects of malachite green. Aquat. Toxicol. 2004, 66:319-329.
30. Stanfield P.R. Tetraethylammonium ions and the potassium permeability of excitable cells. Rev. Physiol. Biochem. Pharmacol. 1983, 97:1-67.
31. Szabo I., Zoratti M., Gulbins E. Contribution of voltage-gated potassium channels to the regulation of apoptosis. FEBS Lett. 2010, 584:8.
32. Tao H., Santa Ana D., Guia A., Huang M., Ligutti J., Walker G., Sithiphong K., Chan F., Guoliang T., Zozulya Z., Saya S., Phimmachack R., Sie C., Yuan J., Wu L., Xu J., Ghetti A. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol. 2004, 2:497-506.
33. Thomas D., Gut B., Karsai S., Wimmer A.B., Wu K., Wendt-Nordahl G., Zhang W., Kathofer S., Schoels W., Katus H.A., Kiehn J., Karle C.A. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn-Schmiedebergs Arch. Pharmacol. 2003, 368:41-48.
34. Titus S.A., Beacham D., Shahane S.A., Southall N., Xia M., Huang R., Hooten E., Zhao Y., Shou L., Austin C.P., Zheng W. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal. Biochem. 2009, 394:30-38.
35. Trump D.L., Smith D.C., Ellis P.G., Rogers M.P., Schold S.C., Winer E.P., Panella T.J., Jordan V.C., Fine R.L. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J. Natl Cancer Inst. 1992, 84:1811-1816.
36. Tseng G.N. I(Kr): the hERG channel. J. Mol. Cell. Cardiol. 2001, 33:835-849.
37. Tunctan B., Altug S., Uludag O., Abacioglu N. Effects of econazole on receptor-operated and depolarization-induced contractions in rat isolated aorta. Life Sci. 2000, 67:2393-2401.
38. Vandenberg J.I., Walker B.D., Campbell T.J. HERG K+ channels: friend and foe. Trends Pharmacol. Sci. 2001, 22:240-246.
39. Vandenberg J.I., Torres A.M., Campbell T.J., Kuchel P.W. The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics. Eur. Biophys. J. 2004, 33:89-97.
40. Veraldi S., Milani R. Topical fenticonazole in dermatology and gynaecology: current role in therapy. Drugs 2008, 68:2183-2194.
41. Warmke J.W., Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl Acad. Sci. USA 1994, 91:3438-3442.
42. Winder C., Balouet J.C. The toxicity of commercial jet oils. Environ. Res. 2002, 89:146-164.
43. Wray D. The roles of intracellular regions in the activation of voltage-dependent potassium channels. Eur. Biophys. J. 2004, 33:194-200.
44. Xia M., Imredy J.P., Koblan K.S., Bennett P., Connolly T.M. State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format. Anal. Biochem. 2004, 327:74-81.
45. Xia M., Huang R., Witt K.L., Southall N., Fostel J., Cho M.H., Jadhav A., Smith C.S., Inglese J., Portier C.J., Tice R.R., Austin C.P. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ. Health Perspect. 2008, 116:284-291.
46. Xia M., Huang R., Sun Y., Semenza G.L., Aldred S.F., Witt K.L., Inglese J., Tice R.R., Austin C.P. Identification of chemical compounds that induce HIF-1alpha activity. Toxicol. Sci. 2009, 112:153-163.
47. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.